Maximilien Vermandel presents Hemerion, a French company dedicated to innovative cancer therapies. скачать в хорошем качестве

Maximilien Vermandel presents Hemerion, a French company dedicated to innovative cancer therapies.

Founder and CEO of Hemerion, Maximilien Vermandel presents the Hemerion company and its clinical achievements in the fight against glioblastoma, the most widespread and agressive brain tumor. Glioblastoma is the most common and most devastating malignant brain tumor. There is no known cure for this disease: the tumor progression is only slowed and reduced through surgery, radiotherapy and chemotherapy. Hemerion technology dramatically improves the existing treatment outcomes, patients’ survival and quality of life. Hemerion addresses upfront management of newly diagnosed glioblastoma, during surgery, before any adjuvant treatment or drug can be delivered, making Hemerion technology a breakthrough innovation. This treatment is based on a photosensitizing drug (Pentalafen), administered to the patient before surgery, and an exclusive photonic system (Heliance illumination solution). This unique drug-device combination therapy selectively destroys cancer cells, in areas inaccessible to classic surgery and without harming healthy tissues. Hemerion technology relies on a drug that is a precursor of the photosensitizer that selectively accumulates in dysplastic cells. Indeed, our drug converts to a photosensitive molecule that is 200 times more concentrated in cancer cells than in normal cells, ensuring a high level of selectivity. Illuminated by specific laser light, the photosensitizer causes tumorous cells death through photochemical cytotoxic effect. The Hemerion Drug+Device combination therapy seamlessly integrates in the current standard of care and can potentially greatly enhance patients outcomes. Hemerion therapeutic solution can be integrated into any upfront surgical procedure used for glioblastoma resection. It can be used multiple times along the disease evolution alongside neurosurgery operations. Designed by neurosurgeons, the Hemerion technology is easy to implement and can be mastered by operating teams with just one week of training. Fully integrated laser system to deliver intraoperative therapy Seamless workflow to push the limits of brain surgery Automatic illumination regimen computation Fully controlled treatment delivery Personalized patient’s dosimetry Hemerion technology is based on well mastered drugs and equipment: it constitutes a very affordable solution. Hemerion’s technology and therapeutic concept have undergone extensive preclinical and clinical validation studies. The clinical development of Hemerion’s solutions continues at a rapid pace. Our goal is to bring our therapies to glioblastoma patients as soon as possible.